{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:46:40Z","timestamp":1791906400432,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bevacizumab-induced gastrointestinal perforation is a potentially fatal adverse event. However, duodenal perforations are rare. Conversely, patients with cancer often have concomitant rheumatoid arthritis and may be treated with a combination of anti-rheumatic drugs and symptomatic medications; however, the effects of these concomitant medications on bevacizumab-related perforation remain understudied. This report describes the case of a patient with ovarian cancer and a history of anti-rheumatic drug treatment who developed early-onset duodenal perforation during bevacizumab-containing chemotherapy, highlighting the importance of assessing the risk of duodenal perforation and the provision of multidisciplinary management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>The patient was a woman in her 50s with ovarian cancer that metastasized to the para-aortic lymph nodes. She was diagnosed with platinum-sensitive recurrence, and combination therapy with gemcitabine, carboplatin, and bevacizumab was initiated. She was also taking iguratimod and methotrexate for rheumatoid arthritis treatment. The patient developed sudden abdominal pain during the second course of chemotherapy and presented to the emergency department. A computed tomography (CT) scan revealed free gas, raising the suspicion of gastrointestinal perforation. Emergency laparotomy confirmed a duodenal perforation that was surgically covered with the ligamentum teres hepatis. A perforation of &lt;1\u2009cm was found in the anterior wall of the duodenal bulb, but the postoperative course was uneventful. The patient was discharged on postoperative day 7 and continued chemotherapy without bevacizumab. Postoperative upper endoscopy revealed an H2 stage ulcer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>When administering bevacizumab to patients with ovarian cancer and multiple perforation risk factors, careful consideration should be given to evaluating existing ulcers, appropriately using concomitant medications, and modifying perforation risk factors to avoid serious adverse events. Therefore, collaboration between a multidisciplinary team, including oncologists, rheumatologists, and pharmacists, is crucial for appropriate drug use and continuous monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00608-9","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:54:39Z","timestamp":1784224479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early-onset duodenal perforation during bevacizumab-containing chemotherapy in a patient with ovarian cancer: a case report"],"prefix":"10.1186","volume":"12","author":[{"given":"Satoshi","family":"Nagase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shokei","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"2","key":"608_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10456-010-9197-6","volume":"14","author":"M Walraven","year":"2011","unstructured":"Walraven M, Witteveen PO, Lolkema MPJ, van Hillegersberg R, Voest EE, Verheul HMW. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis. 2011;14(2):135\u201341. https:\/\/doi.org\/10.1007\/s10456-010-9197-6.","journal-title":"Angiogenesis"},{"issue":"3","key":"608_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.critrevonc.2013.10.002","volume":"89","author":"W-X Qi","year":"2014","unstructured":"Qi W-X, Sun Y-J, Tang L-N, Shen Z, Yao Y. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol\/Hematol. 2014;89(3):394\u2013403. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.10.002.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"6","key":"608_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jscr\/rjaa174","volume":"2020","author":"M Karanikas","year":"2020","unstructured":"Karanikas M, Kofina K, Potolidis D, Foutzitzi S, Deftereos S, Effraemidou E, et al. Spontaneous massive duodenal perforation after ovarian cancer treatment with bevacizumab. J Surg Case Rep. 2020;2020(6):1\u20133. https:\/\/doi.org\/10.1093\/jscr\/rjaa174.","journal-title":"J Surg Case Rep"},{"issue":"6","key":"608_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","volume":"10","author":"S Hapani","year":"2009","unstructured":"Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. The Lancet Oncol. 2009;10(6):559\u201368. https:\/\/doi.org\/10.1016\/S1470-2045(09)70112-3.","journal-title":"The Lancet Oncol"},{"issue":"7","key":"608_CR5","first-page":"437","volume":"111","author":"S Sliesoraitis","year":"2011","unstructured":"Sliesoraitis S, Tawfik B. Bevacizumab-induced bowel perforation. J Am Osteopath Assoc. 2011;111(7):437\u201341.","journal-title":"J Am Osteopath Assoc"},{"issue":"1","key":"608_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13256-018-1619-x","volume":"12","author":"Y Fujii","year":"2018","unstructured":"Fujii Y, Hirahara N, Kaji S, Taniura T, Hyakudomi R, Yamamoto T, et al. Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature. J Med Case Rep. 2018;12(1):84. https:\/\/doi.org\/10.1186\/s13256-018-1619-x.","journal-title":"J Med Case Rep"},{"issue":"3","key":"608_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/annonc\/mdm508","volume":"19","author":"BD Badgwell","year":"2008","unstructured":"Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol. 2008;19(3):577\u201382. https:\/\/doi.org\/10.1093\/annonc\/mdm508.","journal-title":"Ann Oncol"},{"issue":"1","key":"608_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12957-023-03058-x","volume":"21","author":"MH Storandt","year":"2023","unstructured":"Storandt MH, Tran NH, Ehret CJ, Hanna M, Jochum J, Moynagh MR, et al. Gastrointestinal perforation after bevacizumab: a multi-site, single-institution study with a focus on survival. World J Surg Oncol. 2023;21(1):177. https:\/\/doi.org\/10.1186\/s12957-023-03058-x.","journal-title":"World J Surg Oncol"},{"issue":"3","key":"608_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/ar3352","volume":"13","author":"K Elandt","year":"2011","unstructured":"Elandt K, Aletaha D. Treating rheumatic patients with a malignancy. Arthritis Res Ther. 2011;13(3):223. https:\/\/doi.org\/10.1186\/ar3352.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"608_CR10","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788\u201395. https:\/\/doi.org\/10.1038\/sj.bjc.6603813.","journal-title":"Br J Cancer"},{"issue":"4","key":"608_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10637-008-9125-4","volume":"26","author":"J Tol","year":"2008","unstructured":"Tol J, Cats A, Mol L, Koopman M, Bos MMEM, van der Hoeven JJM, et al. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs. 2008;26(4):393\u201397. https:\/\/doi.org\/10.1007\/s10637-008-9125-4.","journal-title":"Invest New Drugs"},{"issue":"8","key":"608_CR12","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ejca.2012.02.052","volume":"48","author":"FF Kabbinavar","year":"2012","unstructured":"Kabbinavar FF, Flynn PJ, Kozloff M, Ashby MA, Sing A, Barr CE, et al. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer. 2012;48(8):1126\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2012.02.052.","journal-title":"Eur J Cancer"},{"issue":"3","key":"608_CR13","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.21873\/invivo.13947","volume":"39","author":"K Saito","year":"2025","unstructured":"Saito K, Nihei S, Asaka J, Kudo K. Adverse reactions with VEGF inhibitors in combination with NSAIDs: disproportionality analysis using JADRE and FAERS. In Vivo. 2025;39(3):1458\u201369. https:\/\/doi.org\/10.21873\/invivo.13947.","journal-title":"In Vivo"},{"issue":"11","key":"608_CR14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/aje\/153.11.1089","volume":"153","author":"S Hernandez-Diaz","year":"2001","unstructured":"Hernandez-Diaz S, Rodriguez LAG. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol. 2001;153(11):1089\u201393. https:\/\/doi.org\/10.1093\/aje\/153.11.1089.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"608_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/14397595.2018.1460230","volume":"29","author":"T Mimori","year":"2019","unstructured":"Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, et al. Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: final report of a 52-week, multicenter postmarketing surveillance study. Mod Rheumatol. 2019;29(2):314\u201323. https:\/\/doi.org\/10.1080\/14397595.2018.1460230.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"608_CR16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/14397595.2018.1481565","volume":"29","author":"K Ishikawa","year":"2019","unstructured":"Ishikawa K, Ishikawa J. Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-\u03baB and production of RANKL: its efficacy, radiographic changes, safety and predictors over two years\u2019 treatment for Japanese rheumatoid arthritis patients. Mod Rheumatol. 2019;29(3):418\u201329. https:\/\/doi.org\/10.1080\/14397595.2018.1481565.","journal-title":"Mod Rheumatol"},{"issue":"5","key":"608_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1001\/jama.2011.51","volume":"305","author":"V Ranpura","year":"2011","unstructured":"Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients. JAMA. 2011;305(5):487\u201394. https:\/\/doi.org\/10.1001\/jama.2011.51.","journal-title":"JAMA"},{"issue":"17","key":"608_CR18","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without Bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or Fallopian tube cancer. JCO. 2012;30(17):2039\u201345. https:\/\/doi.org\/10.1200\/JCO.2012.42.0505.","journal-title":"JCO"},{"issue":"26","key":"608_CR19","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Gynecologic oncology group, incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473\u201383. https:\/\/doi.org\/10.1056\/NEJMoa1104390.","journal-title":"N Engl J Med"},{"issue":"8","key":"608_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonz\u00e1lez-Mart\u00edn A, Marth C, et al. PAOLA-1\/ENGOT-ov25 investigators, Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol. 2023;34(8):681\u201392. https:\/\/doi.org\/10.1016\/j.annonc.2023.05.005.","journal-title":"Ann Oncol"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00608-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00608-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00608-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:04:39Z","timestamp":1791903879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00608-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["608"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00608-9","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report. This case report was not subjected to review by the Ethics Committee of the Saiseikai Yokohamashi Tobu Hospital, and approval was obtained for publication.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"89"}}